Sympathetic activation: a potential link between comorbidities and COVID‐19
Citations Over TimeTop 1% of 2020 papers
Abstract
In coronavirus disease 2019 (COVID-19), higher morbidity and mortality are associated with age, male gender, and comorbidities, such as chronic lung diseases, cardiovascular pathologies, hypertension, kidney diseases, diabetes mellitus, and obesity. All of the above conditions are characterized by increased sympathetic discharge, which may exert significant detrimental effects on COVID-19 patients, through actions on the lungs, heart, blood vessels, kidneys, metabolism, and/or immune system. Furthermore, COVID-19 may also increase sympathetic discharge, through changes in blood gases (chronic intermittent hypoxia, hyperpnea), angiotensin-converting enzyme (ACE)1/ACE2 imbalance, immune/inflammatory factors, or emotional distress. Nevertheless, the potential role of the sympathetic nervous system has not yet been considered in the pathophysiology of COVID-19. In our opinion, sympathetic overactivation could represent a so-far undervalued mechanism for a vicious circle between COVID-19 and comorbidities.
Related Papers
- → Comorbidity in head and neck cancer: A critical appraisal and recommendations for practice(2010)238 cited
- → Elderly patients with head and neck cancer: the influence of comorbidity on choice of therapy, complication rate, and survival(2005)66 cited
- → Health Care Resource Utilization And Costs Associated With HIV-Positive Patients With Comorbidity Versus HIV-Negative Patients With Comorbidity(2017)4 cited
- Influence of comorbidity on the choice of treatment and survival of elderly patients with advanced non-small cell lung cancer(2008)
- → Comorbidity Index(2017)